Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Daren R Ure"'
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0301711 (2024)
A family of Peptidyl-prolyl isomerases (PPIases), called Cyclophilins, localize to numerous intracellular and extracellular locations where they contribute to a variety of essential functions. We previously reported that non-immunosuppressive pan-cyc
Externí odkaz:
https://doaj.org/article/155fcb9d4a9f4cb581ddc2467fa1681a
Autor:
Winston T Stauffer, Asha Z Goodman, Michael Bobardt, Daren R Ure, Robert T Foster, Philippe Gallay
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0298211 (2024)
Cyclophilins are a diverse family of peptidyl-prolyl isomerases (PPIases) of importance in a variety of essential cellular functions. We previously reported that the pan-cyclophilin inhibitor drug reconfilstat (CRV431) decreased disease in mice under
Externí odkaz:
https://doaj.org/article/19d47efbe885491990eac842c64e51d5
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 21, Iss 1s (2018)
PURPOSE: The objective of this study was to develop a self-microemulsifying drug delivery system (SMEDDS) formulation for the oral delivery of CRV431, a non-immunosuppressive analogue of cyclosporine A. Relative to cyclosporine A, CRV431 is poorly so
Externí odkaz:
https://doaj.org/article/26108c1c0720412b98a268ee461267f1
Autor:
Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok, Robert T. Foster
Publikováno v:
Hepatology Communications, Vol 6, Iss 12, Pp 3379-3392 (2022)
Abstract Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers
Externí odkaz:
https://doaj.org/article/3d1b62b8d5934a7da35bda5d34e3a0aa
Autor:
Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok, Robert T. Foster
Publikováno v:
Hepatology Communications. 6:3379-3392
Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers in subjec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93c154d47e3b84d0c8b1c3ba9e00a193
https://doi.org/10.1002/hep4.2100
https://doi.org/10.1002/hep4.2100
Publikováno v:
Pharmaceutics, Vol 9, Iss 4, p 51 (2017)
The cytochrome P450-mediated Phase I in vitro metabolism of CRV431 was studied using selective chemical inhibition and recombinant human enzymes. Additionally, the metabolic profile of CRV431 in human, rat, and monkey liver microsomes was investigate
Externí odkaz:
https://doaj.org/article/46d2482bcad743d985907da80fe93b30
Autor:
Philippe Gallay, Robert T. Foster, Michael Bobardt, Patrick R. Mayo, Daren R. Ure, Magnus Hansson
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 8, p e0237236 (2020)
PLoS ONE, Vol 15, Iss 8, p e0237236 (2020)
We previously reported that the non-immunosuppressive cyclophilin inhibitors (CypIs)-cyclosporin A analog CRV431 and sanglifehrin analog NV556-efficiently inhibit HCV replication in vitro. In this study, we asked whether they can also reduce HCV repl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d7255e50ff769298a02ed8efce16d2
http://europepmc.org/articles/PMC7413547
http://europepmc.org/articles/PMC7413547
Autor:
Haoning Howard Cen, Robert B Huizinga, Jelena Kolic, James D. Johnson, Leanne Beet, Evgeniy Panzhinskiy, Daren R Ure, Peter Overby, Jennifer L Cross
Publikováno v:
Endocrinology
ContextThe incidence of new onset diabetes after transplant (NODAT) has increased over the past decade, likely due to calcineurin inhibitor-based immunosuppressants, including tacrolimus (TAC) and cyclosporin (CsA). Voclosporin (VCS), a next generati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928f288c579be8ec781b6379db45f87
https://doi.org/10.1101/2020.04.30.071324
https://doi.org/10.1101/2020.04.30.071324
Autor:
Philippe Gallay, Udayan Chatterji, Daren R. Ure, Robert T. Foster, Patrick R. Mayo, Daniel J. Trepanier, Joseph Kuo, Michael Bobardt
Publikováno v:
The Journal of Pharmacology and Experimental Therapeutics
Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode of action has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::253eb60f5a565c81480e5b881bf2cf94
https://pubmed.ncbi.nlm.nih.gov/31406003
https://pubmed.ncbi.nlm.nih.gov/31406003
Autor:
Michael Bobardt, Philippe Gallay, Daren R. Ure, James Ou, Udayan Chatterji, Daniel J. Trepanier, Robert T. Foster
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 6, p e0217433 (2019)
PLoS ONE, Vol 14, Iss 6, p e0217433 (2019)
Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their suppression of HBV replication, but the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9260539662eca25b92ea9a83e05cd7e
https://pubmed.ncbi.nlm.nih.gov/31181107
https://pubmed.ncbi.nlm.nih.gov/31181107